CTI BioPharma Corp  

(Public, NASDAQ:CTIC)   Watch this stock  
Find more results for CTIC
0.00 (0.00%)
Jan 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.41 - 3.50
52 week 2.45 - 5.28
Open 3.46
Vol / Avg. 247,080.00/168,353.00
Mkt cap 150.39M
P/E     -
Div/yield     -
EPS -1.03
Shares 42.97M
Beta 0.53
Inst. own 45%
Feb 28, 2018
Q4 2017 CTi Biopharma Corp Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 15, 2017
CTi Biopharma Corp at Jefferies Global Healthcare Conference
Nov 6, 2017
Q3 2017 CTi Biopharma Corp Earnings Call - Webcast
Nov 6, 2017
Q3 2017 CTi Biopharma Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -703.75% -92.24%
Operating margin -690.15% -85.64%
EBITD margin - -84.19%
Return on average assets -63.38% -50.91%
Return on average equity -125.46% -159.17%
Employees 100 -
CDP Score - -


3101 Western Ave Ste 800
SEATTLE, WA 98121-3017
United States - Map
+1-206-2827100 (Phone)
+1-206-2846206 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.

Officers and directors

Laurent Fischer M.D. Chairman of the Board
Age: 52
Bio & Compensation  - Reuters
Adam R. Craig M.D., Ph.D. President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
David H. Kirske Chief Financial Officer, Executive Vice President
Age: 62
Bio & Compensation  - Reuters
Bruce J. Seeley Chief Operating Officer
Age: 53
Bio & Compensation  - Reuters
Jack W. Singer M.D. Interim Chief Medical Officer, Global Head of Translational Medicine, Executive Vice President, Chief Scientific Officer
Age: 72
Bio & Compensation  - Reuters
Nancy L. Boman Ph.D. Senior Vice President of Clinical Development and Regulatory Affairs
Bio & Compensation  - Reuters
Monique M. Greer Senior Vice President of Corporate Communications and Investor Relations
Age: 48
Bio & Compensation  - Reuters
Michael A. Metzger Director
Age: 45
Bio & Compensation  - Reuters
Matthew Perry Director
Bio & Compensation  - Reuters
David Ross Parkinson M.D. Independent Director
Age: 67
Bio & Compensation  - Reuters